Leading 10 Biotechnology Companies Generated Annual Revenue of $77.85 Billion in 2010: PharmaLive Special Report

NEWTOWN, Pa., August 9, 2011-The recent acquisition of Genzyme by Sanofi and the announcement that Teva will acquire Cephalon demonstrate that the gap between the pharmaceutical and biotechnology industries continues to narrow. Companies conduct aggressive mergers as pipelines and new drug approvals lack blockbuster options, the patent cliff grows, and U.S. healthcare reform takes shape.

Biotech companies in the industry's traditional centers of Australia, Canada, Europe, and the United States had a record-breaking 2010 with a 30% net profit increase compared to 2009. Companies in these markets reportedly combined for an aggregate net profit of $4.7 billion. Excluding Australia, biotech players in the other three markets raised $25 billion in capital during 2010.

In 2010, the top 10 biotech companies had combined revenue of $77.85 billion, up from $75.59 billion in 2009. The top 10 companies per 2010 revenue were Roche, Amgen, Gilead Sciences, Biogen Idec, UCB, Genzyme, CSL, Celgene, Cephalon, and Actelion.

"Two of the top 10 biotech revenue generators from last year have been acquired during 2011, and there could be another leader or two gobbled up within the next year," says Andrew Humphreys, editor in chief of UBM Canon Data Products. "Big Pharma will continue to pursue innovative biotechnology and biopharmaceutical entities in an effort to offset blockbuster patent expirations and a lack of promising pipelines products."

Switzerland's Roche generated SFr47.5 billion in revenue in 2010 with overall R&D investments totaling SFr10.0 billion. Roche is an innovator of products and services used in the early detection, prevention, diagnosis and treatment of several diseases. The company's mission is to create additional value in healthcare by focusing its expertise in diagnostics and pharmaceuticals. As the largest biotech company globally, Roche medicines span across areas such as oncology, virology, inflammation, metabolism, and CNS.

Since its initial U.S. approval in 2004 for the treatment of colorectal cancer, the blockbuster drug Avastin has grown to include indications for several types of cancers. The drug is approved in the United States and Europe for the treatment of advanced stages of colorectal cancer, breast cancer, non-small cell lung cancer, and kidney cancer. Avastin is Roche's top-selling product and was the No. 7 seller among prescription medicines worldwide in 2010, earning $6.19 billion.

More information is available in Top 50 Biotechnology Companies and Their Pipelines 2011, located at www.pharmalive.com/specialreports.

 

For additional information, contact Sandra Baker at +1-215-944-9836 or Sandra.Baker@ubm.com.

 

About UBM Canon Data Products

UBM Canon Data Products provide financial, company, and product statistical data and qualitative analysis for the global pharmaceutical, biotechnology, medical device, and appliance industries through PharmaLive Special Reports and Appliance Market Research Reports; maintains eKnowledgeBase and MDRWeb, comprehensive market intelligence tools serving the pharmaceutical, biotechnology, and medical-device sectors; and manages company-wide Site Licenses for PharmaLive.com, Med Ad News, and R&D Directions.

 

About UBM Canon

UBM Canon is a business-to-business media company serving the worldwide advanced manufacturing sector through its publications, trade events, and electronic media.

 

Contact:

Amanda Wells

+1-215-944-9840

Amanda.wells@ubm.com


 

Posted: August 2011


View comments

Hide
(web5)